Virus-Like Particles with Exposed HIV Epitopes for Mucosal Immunity
Solution Overview
Problem
Current vaccine approaches face challenges in effectively inducing neutralizing antibodies against highly variable and glycosylated HIV envelope proteins, and in eliciting strong mucosal immune responses against HIV and other viruses, due to difficulties in targeting antigens to mucosal sites and the presence of obstructing structural features that shield neutralizing epitopes.
Innovation Solution
Development of virus-like particles (VLPs) that incorporate modified HIV envelope glycoproteins with exposed neutralizing epitopes and adjuvant molecules like influenza HA, which self-assemble to present conformational epitopes and target mucosal surfaces, enhancing immune responses through intranasal administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If soluble envelope antigens are used as vaccine antigens, then the vaccine can be easily manufactured, but the ability to induce neutralizing antibodies is reduced
Solution Approach 1:
The patent combines envelope glycoproteins with virus-like particle cores to create composite vaccine antigens. The VLP structure provides a particulate framework that displays multiple copies of the envelope glycoprotein in a spatial arrangement mimicking native viral surfaces, thereby enhancing neutralizing antibody induction while maintaining manufacturability through recombinant expression systems.
Solution Approach 2:
The patent utilizes spherical virus-like particle structures to display envelope glycoproteins. This spherical configuration presents the glycoproteins in a three-dimensional arrangement that better mimics the native viral surface topology compared to soluble antigens, improving the induction of conformational-specific neutralizing antibodies.
2Ease of operation
If conventional vaccine approaches are used, then the vaccine can be administered, but strong mucosal immune responses cannot be elicited
Solution Approach 1:
The patent modifies the physical parameters of the vaccine antigen by using particulate VLP structures instead of soluble proteins. This size and structural parameter change enables the vaccine to be targeted to mucosal sites and stimulates stronger mucosal immune responses including secretory IgA production, while maintaining ease of administration through standard injection or mucosal delivery routes.
3Ease of manufacture
If envelope glycoproteins with obstructing structural features are used, then the antigen can be produced, but neutralizing epitopes are shielded from immune recognition
Solution Approach 1:
The patent segments the envelope glycoprotein structure by expressing it as a trimeric complex on the VLP surface. This segmentation into functional subunits (gp120 and gp41) that self-assemble into trimers exposes the neutralizing epitopes on the gp120 subunits while maintaining the structural integrity needed for production. The trimeric arrangement prevents the immunodominant but non-neutralizing V3 loops from completely shielding the critical epitopes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The VLPs induce robust humoral and cellular immune responses, including neutralizing antibodies and mucosal immunity, by presenting modified HIV envelope proteins with exposed epitopes and utilizing adjuvant molecules to target mucosal surfaces effectively.
Implementation Method 1
a viral core protein that can self-assemble into the VLP core
Data Source
AI summary
Briefly described, virus-like particles, methods of preparing virus-like particles, immunogenic compositions that include virus-like particles, and methods of eliciting an immune response using immunogenic compositions that include virus-like particles are described herein. A virus-like particle (VLP) can include a viral core protein that can self assemble into the VLP core and at least one viral surface envelope glycoprotein expressed on the surface of the VLP. The VLP can also optionally include at least one adjuvant molecule expressed on the surface of the VLP.